Effect of intra-peritoneal fludarabine on rat spinal cord tolerance to fractionated irradiation.
The effect of fludarabine (9-beta-D-arabinosyl-2-fluoroadenine-5'- monophosphate), an adenine nucleoside analogue, on the tolerance of the spinal cord to fractionated irradiation was studied in a rat model. Anesthetized female Fisher 344 rats received irradiation to 2 cm of the cervical spine with a telecobalt unit (dose rate 1.14 Gy/min). Radiation was administered in two, four or eight fractions spread over a 48-h period with or without fludarabine. Animals assigned to combined therapy received two daily intraperitoneal injections of fludarabine (150 mg/kg) given 3 h prior to the first daily radiation fraction. It was found that fludarabine reduced the iso-effect dose required to induce leg paresis at 9 months after irradiation for all fractionation schedules. Dose modification factors of 1.23, 1.29 and greater than 1.27 were obtained for two, four and eight fractions, respectively. Fitting the data with the direct analysis method of Thames et al. with an incomplete repair model [18] showed that the potentiating effect of fludarabine may be mediated through reduction in the number of 'tissue-rescuing units' (InK). Alpha and beta values were slightly but not significantly decreased, whereas the alpha/beta ratio was unchanged. These features suggest that fludarabine did not significantly inhibit cellular repair processes but rather reduced the spinal cord tolerance by a fixed additive toxic effect on the same target cells. In rodent models, the combination of fludarabine and fractionated radiation has previously been found to yield a therapeutic gain, i.e., the drug enhanced tumor response to a greater extent than it reduced normal tissue tolerance.(ABSTRACT TRUNCATED AT 250 WORDS)
Department of Clinical Investigation, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.
V
V
Grégoire
A C
AC
Ruifrok
R E
RE
Price
W A
WA
Brock
W N
WN
Hittelman
W K
WK
Plunkett
K K
KK
Ang
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D003037:Cobalt Radioisotopes; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005500:Follow-Up Studies; D006614:Hindlimb / Q000528:radiation effects; D007274:Injections, Intraperitoneal; D010291:Paresis / Q000209:etiology; D011829:Radiation Dosage; D011833:Radiation Injuries, Experimental / Q000209:etiology; D011836:Radiation Tolerance / Q000187:drug effects*; D011867:Radioisotope Teletherapy / Q000295:instrumentation; D051381:Rats; D011916:Rats, Inbred F344; D013116:Spinal Cord / Q000187:drug effects* / Q000528:radiation effects*; D013997:Time Factors; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
D000970:Antineoplastic Agents; D003037:Cobalt Radioisotopes; D014740:Vidarabine; C024352:fludarabine